The primary endpoint of 12-month Event Free Survival (EFS) for OST-HER2- treated patients (33.3%) was statistically significant (p= 0.0158) when compared with peer-reviewed comparable historical control (20%)
Ongoing follow up demonstrates strong trend in favor of OST-HER2 in 1-year and 2-year interim analyses of the secondary endpoint, 3-year overall survival (OS) when compared with comparable peer-reviewed historical control
100% of patients who achieved 12-month EFS remain alive in OS follow-up
OST-HER2 was safe and well tolerated in the Phase 2b study
OS Therapies reiterates clinical and regulatory path in recurrent, fully resected osteosarcoma with lung metastases, an indication with no currently approved treatments
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.